Novo Nordisk CEO Embraces Risk to Diversify Beyond Ozempic
Novo Nordisk's CEO Mike Doustdar signals openness to large deals and acknowledges potential failures in efforts to reduce dependency on weight-loss drugs.
On August 4, 2026, Financial Times reported that Mike Doustdar, CEO of Novo Nordisk, the maker of Ozempic, emphasized the importance of risk-taking as the company seeks to diversify its business. Doustdar stated that the group is open to large acquisitions and anticipates experiencing failures as it attempts to cut reliance on its popular weight-loss drug, Ozempic.
Sources
Financal Times — ‘Arrogance kills’: Novo chief injects risk-taking into Ozempic makerTHE QUESTIONS THIS EVENT LEAVES BEHIND